


Claims:

1. A compound having the general structure:



10 wherein R<sub>1</sub>, R<sub>7</sub> and R<sub>8</sub> are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R<sub>3</sub> is hydroxy or -OC(=O)NH<sub>2</sub>; and


R<sub>4</sub> is hydroxy or carbonyl.

- 15 2. The compound of claim 1 wherein R<sub>1</sub> is H or halo; and

R<sub>7</sub> and R<sub>8</sub> are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy.

- 20 3. The compound of claim 2 wherein R<sub>4</sub>, R<sub>7</sub> and R<sub>8</sub> are H; and  
R<sub>1</sub> is H or F.

4. A compound having the general structure:



wherein R<sub>1</sub>, R<sub>7</sub> and R<sub>8</sub> are independently selected from the group consisting of H, halo, haloalkyl and hydroxy; and


R<sub>3</sub> is hydroxy or -OC(=O)NH<sub>2</sub>, with the proviso that at least one of R<sub>1</sub>, R<sub>7</sub> and R<sub>8</sub> is other than H.

- 30 5. The compound of claim 4 wherein R<sub>7</sub> and R<sub>8</sub> are H;  
R<sub>1</sub> is F; and


R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>.

6. A method for treating a patient suffering from a neurological disorder, said method comprising the step of administering a composition comprising a compound selected from the group consisting of

10



15



20

wherein R<sub>1</sub>, R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub> are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;


R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>; and

R<sub>4</sub> is hydroxy or carbonyl, with the proviso that when R<sub>9</sub> is H, R<sub>7</sub>


and R<sub>8</sub> are not both H.

7. The method of claim 6 wherein said compound has the general structure

25



30




wherein R<sub>1</sub> is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>.

- 5            8.        The method of claim 7 wherein R<sub>1</sub> is H; and  
                 R<sub>3</sub> is -OCONH<sub>2</sub>.

- 10            9.        A method for treating a patient suffering from tissue damage resulting from localized hypoxic conditions, said method comprising the step of administering a composition comprising a compound selected from the group consisting of




wherein R<sub>1</sub>, R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub> are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>; and

- 25            R<sub>4</sub> is hydroxy or carbonyl, with the proviso that when R<sub>9</sub> is H, R<sub>7</sub> and R<sub>8</sub> are not both H..

- 30            10.      The method of claim 9 wherein said compound has the general structure



wherein R<sub>1</sub> is selected from the group consisting of H, halo, haloalkyl and hydroxy; and


R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>.

15        11.     The method of claim 10 wherein R<sub>1</sub> is H; and  
                 R<sub>3</sub> is -OCONH<sub>2</sub>.


20        12.     The method of claim 9 wherein the localized hypoxic condition is caused by cerebral ischemia.

13.     The method of claim 9 wherein the localized hypoxic condition is caused by myocardial ischemia.

25        14.     A pharmaceutical composition comprising a compound selected from the group consisting of



10



wherein R<sub>1</sub>, R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub> are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

15

R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>; and


R<sub>4</sub> is hydroxy or carbonyl, with the proviso that when R<sub>9</sub> is H, R<sub>7</sub> and R<sub>8</sub> are not both H; and

a pharmaceutically acceptable carrier.,


20

15. The composition of claim 14 wherein said compound has the general structure

25



30



-40-

wherein R<sub>1</sub> is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>.

5

16. The composition of claim 15 wherein R<sub>1</sub> is selected from the group consisting of halo, haloalkyl and hydroxy.

17. The composition of claim 15 wherein R<sub>1</sub> is H; and  
R<sub>3</sub> is -OCONH<sub>2</sub>.

10

CONFIDENTIAL SOURCE